PPARG and Parkinson disease: Thus, inhibitors of iNOS or COX-2, purinergic P2X receptor antagonists, pioglitazone, and other PPAR-γ activators, nonsteroidal anti-inflammatory drugs, the antibiotic minocycline, and immunosuppressants have been investigated at the preclinical and clinical levels in PD with variable success [4,5].